-
公开(公告)号：US09867781B2
公开(公告)日：2018-01-16
申请号：US13400382
申请日：2012-02-20
IPC分类号： A61K9/16 , A61K9/00 , A61K31/573 , A61K45/06 , A61K35/39 , G01N33/50 , A61L27/38 , A61L27/48 , A61L27/52 , A61L27/54 , C12N5/071
CPC分类号： A61K9/1641 , A61K9/0019 , A61K31/573 , A61K35/39 , A61K45/06 , A61L27/3804 , A61L27/48 , A61L27/52 , A61L27/54 , A61L2300/41 , A61L2300/622 , A61L2300/64 , C12N5/0676 , C12N2502/1157 , C12N2533/40 , C12N2533/74 , G01N33/5088 , A61K2300/00 , C08L5/04 , C08L5/08
摘要： A composition containing biocompatible hydrogel encapsulating mammalian cells and anti-inflammatory drugs is disclosed. The encapsulated cells have reduced fibrotic overgrowth after implantation in a subject. The compositions contain a biocompatible hydrogel having encapsulated therein mammalian cells and anti-inflammatory drugs or polymeric particles loaded with anti-inflammatory drugs. The anti-inflammatory drugs are released from the composition after transplantation in an amount effective to inhibit fibrosis of the composition for at least ten days. Methods for identifying and selecting suitable anti-inflammatory drug-loaded particles to prevent fibrosis of encapsulated cells are also described. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.
-
公开(公告)号：US20120213708A1
公开(公告)日：2012-08-23
申请号：US13400382
申请日：2012-02-20
CPC分类号： A61K9/1641 , A61K9/0019 , A61K31/573 , A61K35/39 , A61K45/06 , A61L27/3804 , A61L27/48 , A61L27/52 , A61L27/54 , A61L2300/41 , A61L2300/622 , A61L2300/64 , C12N5/0676 , C12N2502/1157 , C12N2533/40 , C12N2533/74 , G01N33/5088 , A61K2300/00 , C08L5/04 , C08L5/08
摘要： A composition containing biocompatible hydrogel encapsulating mammalian cells and anti-inflammatory drugs is disclosed. The encapsulated cells have reduced fibrotic overgrowth after implantation in a subject. The compositions contain a biocompatible hydrogel having encapsulated therein mammalian cells and anti-inflammatory drugs or polymeric particles loaded with anti-inflammatory drugs. The anti-inflammatory drugs are released from the composition after transplantation in an amount effective to inhibit fibrosis of the composition for at least ten days. Methods for identifying and selecting suitable anti-inflammatory drug-loaded particles to prevent fibrosis of encapsulated cells are also described. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.
摘要翻译： 公开了含有包封哺乳动物细胞和抗炎药物的生物相容性水凝胶的组合物。 包被的细胞在植入受试者后具有减少的纤维化过度生长。 所述组合物包含具有包封哺乳动物细胞和抗炎药物或装有抗炎药物的聚合物颗粒的生物相容性水凝胶。 抗炎药从移植后的组合物中以有效抑制组合物纤维化至少十天的量释放。 还描述了鉴定和选择合适的抗炎药物负载颗粒以防止包封细胞纤维化的方法。 还公开了治疗受试者疾病的方法，其涉及向受试者施用治疗有效量的所公开的封闭细胞。
-
搜索结果
2 条记录 (耗时 0.012 秒)
